. b The difference between the average and median performance is due to a few outliers with high RMSD values (Supplementary Table 3 ). A clear tendency was observed for high RMSDs for ligands with more than 11 rotatable bonds. c Values are extracted from ref. [1] figure 10 for the top 1 prediction (as was used by DOCKovalent) note that these averages include 13 more non β--lactam structures. The lower RMSD is reported in these cases. * Note that the original benchmark reported in 3 contained two additional cases 3BEC and 3KGO, however these had non--realistic covalent bond angles and were excluded from the analysis. Fig. 1) . b We report the number of molecules (both ligands and decoys) for which a non--clashing pose was found. E.g. for EGFR poses were found for 50 known inhibitors and 215,000 decoys containing an α,β--unsaturated carbonyl group. c ZINC was filtered for molecules containing the electrophiles. To limit the docking library size for the α/β--unsaturated carbonyl and carbamate libraries we included only lead--like molecules (250 ≤ molecular weight ≤ 350 ; xLogP ≤ 3.5 ; Number of rotatable bonds ≤ 7). d Area Under ROC curve (AUC). 100% corresponds to perfect ranking. 50% corresponds to random ranking. e Adjusted logAUC is a measure for early enrichment 4 , and random ranking corresponds to a logAUC of 0. Supplementary Fig. 15 ) c N/A: < 10% inhibition at 10 μM 
Supplementary

a Number of PDB templates for which this scaffold ranked with any linker in the top 500. b PDB template for which this combination of scaffold and linker scored best. c The best rank of this scaffold with any of the 50 boronic acid aldehyde linkers; the linker that achieved this rank is depicted in the right--most column. d The only candidate chosen using a native Cys909 rotamer (+60), all other compounds were selected based on docking to an alternative Cys rotamer (-60). Table 5 for RMSD values of the entire benchmark.
Supplementary Figure 4. Docking predictions of new boronic acid AmpC inhibitors.
All boronic acids docked to AmpC with a canonical binding mode, where the boronic acid occupies the oxyanion hole consisting of the backbone amides of Ala318 and Ser64, and accepts a hydrogen bond from Tyr150. a,b. Pyridyl boronic acids 2 and 5, respectively, are predicted to hydrogen bond to Asn152 and Gln120 via the pyridine nitrogen and the ether oxygen. c. Indole boronic acid 4 is predicted to stack against Tyr221 and form a hydrogen bond with the backbone carbonyl of Ala318. The hydrophobic benzyl ether is predicted to project into a hydrophobic pocket created by Thr319 and Val211. d. Methoxypyridine 6, which scored poorly in the docking run, was selected for testing because several high--ranking derivatives of this compound were not available for purchase. See Table 1 for the docking ranks, Ki and ligand efficiencies of these inhibitors.
Supplementary Figure 5. AmpC inhibition by analogs of compound 3.
Structures of each boronic acid analog of 3, and the percent inhibition of AmpC at 1 μM inhibitor. This SAR series shows a preference for substitution at the meta position of the phenyl or pyrimidine substituent. Supplementary Notes Supplementary Note 1. Retrospective assessment of covalent docking. We tested method's ability to find known covalent ligands and geometries in retrospective calculations. In a pose recapitulation benchmark of 61 irreversibly bound β--lactams 3 , the ligand structures predicted by DOCKovalent corresponded to the experimental structures with a median RMSD of 2.36 Å (Supplementary Tables  2,3 ), compared to an average 3.4 Å in the earlier study. This control calculation supports at least the ability of the method to recapitulate known geometries.
In addition to predicting geometries, a virtual screening method seeks to discover new ligands. A widely--used control for its ability to do so is to dock libraries composed of annotated ligands combined with decoy molecules that resemble the ligands but are not expected to bind. We therefore compiled libraries of known covalent inhibitors for each of the following five targets: epidermal growth factor receptor kinase (EGFR), fatty acid amide hydrolase (FAAH), acetylcholinesterase (AChE), and HCV protease NS3. The different inhibitors were driven by different electrophiles, including Michael acceptors, carbamates, boronic acids and α--ketoamides (Supplementary Table 4 , Supplementary Fig. 1 ). To these libraries we added all purchasable molecules containing the same electrophiles to serve as decoys (Supplementary Table 4 ). While these "decoy" libraries likely contain genuine covalent inhibitors for these targets, we expected known binders to rank at the top of the hit list.
In four of the five covalent virtual screens, we observed substantial early enrichment of the annotated inhibitors versus the decoy molecules (area under the curve (AUC) of the Receiver Operating Characteristic (ROC) curve > 75%). Thus the adjusted logAUC, a metric that emphasizes early enrichment, was greater than 13.5; an adjusted logAUC of 0 corresponds to random ranking 4 . For NS3, the method performs poorly, likely due to the large number of rotatable bonds in known NS3 inhibitors, which on average had 17.3 rotatable bonds versus between 4.3 and 7.1 rotatable bonds for inhibitors of the other targets.
Supplementary Note 2. Synthetic Chemistry. All purchased chemicals were used as received without further purification. Solvents were dried by passage through columns (either alumina or activated molecular sieves) on a Glass Contour solvent system. NMR spectra were obtained on a Varian Inova 400 MHz spectrometer and referenced to the residual solvent peak. LC--MS analysis was performed on a Waters Acquity LCT UPLC equipped with a TUV detector (monitored at 254 nm) and a Waters Acquity UPLC 1.7 µm C--18 column, eluting at 0.6 mL/min with a 2.5 or 5 minute water:MeCN (with 0.1% formic acid) gradient method. 3-- (4--((1H--1,2,4--triazol--1--yl) methyl)thiophen--2--yl)--2--cyanoacrylamide (19) 4--((1H--1,2,4--triazol--1--yl)methyl)thiophene--2--carbaldehyde (25 mg, 0.129 mmol) was dissolved in THF (0.5 mL) in a vial with a stirbar, to which was added 2--cyanoacetamide (11 mg, 0.129 mmol) and piperidine (12 µL, 0.129 mmol). The reaction was stirred for 7 hours. The precipitate was collected by filtration and dried in vacuo to afford cyanoacrylamide 19 (17 mg, 51%) as a tan solid. 1 
